Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$117.40 - $238.00
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.78M
Market Cap
$18.00B
Enterprise Value$26.68B
Total Cash (Recent Filing)$639.56M
Total Debt (Recent Filing)$1.10B
Price to Earnings (P/E)10.7
Beta0.69
Next Earnings
May 01, 2025EPS Estimate
3.56Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)11.18
Shares Outstanding146,374,940
10 Day Avg. Volume1,759,738
30 Day Avg. Volume1,776,281
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)N/A
Price to Sales (P/S)2.13
Price to Cash Flow (P/CF)6.80
P/FCF Ratio6.30
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.76
Enterprise Value/Ebitda11.63
Forecast
1Y Price Target
$192.24Price Target Upside61.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
---
Bulls Say, Bears Say
Bulls Say
Collaborations And PartnershipsBiogen announced a collaboration with Stoke Therapeutics for the development of a treatment for Dravet syndrome, which aligns with their expertise in neuro, immunology, and rare diseases.
Product PerformanceLeqembi continues its positive trajectory especially in the USA, supporting the real-world data from the academic centers.
Regulatory DevelopmentsThe European Medicines Agency's Committee for Medicinal Products for Human Use reversed its decision and recommended Biogen/Eisai's Leqembi for Alzheimer's patients.
Bears Say
Financial PerformanceThe stock is down 4% as the midpoint of the 2025 EPS guidance is notably below consensus.
Product Portfolio ChallengesFresh pipeline cuts to BIIB113, BIIB093, BIIB101, and BIIB143 (cemdomespib), further trim down Biogen's portfolio, which was lean to start.
Revenue And Growth ChallengesRevenue erosion continues with unclear path to near-term sustained growth.
---
Ownership Overview
0.16% Insiders
32.80% Mutual Funds
22.41% Other Institutional Investors
11.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $117.40 and its highest was $238.00 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $18.00B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is May 01, 2025 which is in 22 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Feb 12, 2025. The company reported $3.44 earnings per share for the quarter, beating the consensus estimate of $3.331 by $0.109.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.225 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 3.56.
How many shares outstanding does Biogen have?
Biogen has 146,374,940 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $3.44 in its last earnings report, beating expectations of $3.331. Following the earnings report the stock price went down -4.276%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
---
Biogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$192.24 (61.29% Upside)
$192.24 (61.29% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 998.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.53%
12-Months-Change
Fundamentals
Return on Equity
10.36%
Trailing 12-Months
Asset Growth
4.49%
Trailing 12-Months
Company Description
Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
---
BIIB Company Deck
---
BIIB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Biogen's earnings call highlighted successful new product launches and operational efficiency, offsetting declines in its multiple sclerosis franchise. However, challenges persist in identifying patients for SKYCLARYS and pressure on MS revenues is expected to continue.Read More>---
BIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
6.74% Contract manufacturing, royalty and other revenue
0.62% Alzheimer's collaboration revenue
---
BIIB Stock 12 Month Forecast
Average Price Target
$192.24
▲(61.29% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
1 Year Success Rate
11/39 ratings generated profit
1 Year Average Return
-9.48%
reiterated a buy rating 2 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 28.21% of your transactions generating a profit, with an average return of -9.48% per trade.
---